Preliminary Program subject to change
15B04 Pharmaceutical Product/Process Development & Scale-up: Part 2
OverviewContinuation of Pharmaceutical Product/Process Development & Scale-up: Part 1 (15B01): This session welcomes submissions detailing studies of pharmaceutical unit operations used to produce final dosage forms. Studies at scales ranging from small-scale pilot plant through production are welcome.
Primary SponsorPharmaceuticals (15b)

CoChair

Michael B. Mackaplow
Abbott Laboratories
Dept. 4P8, Bldg. A4
1401 Sheridan Road
North Chicago, IL 60064-6235
Phone Number: 847-938-0808
Fax Number: 847-785-2220
Email: michael.b.mackaplow@abbott.com

CoChair

John F. Peragine
Principal Technical Investigator
Bristol-Myers Squibb Company
1 Squibb Drive
Bldg. 137 rm 389
New Brunswick, NJ 08903
Phone Number: 732 227-5688
Fax Number: 732 227-3892
Email: john.peragine@bms.com
Approaches to Accelerating Pharmaceutical Process Development and Scale-up
Jeffrey Givand, Brad Holstine, Edward Smith, Lawrence Rosen and James Zega, Pharmaceutical R&D, Merck & Co., Inc., West Point, PA 19486
The Role of Simulation and Scheduling Tools in the Development and Manufacturing of Pharmaceutical Products
Demetri P. Petrides, INTELLIGEN, INC., 2326 Morse Avenue, Scotch Plains, NJ 07076 and Charles Siletti, INTELLIGEN, INC., 700 Walton Ave., Mount Laurel, NJ 08054
An Informatics Framework for Pharmaceutical Product Development
Chunhua Zhao1, Ankur Jain1, Leaelaf M. Hailemariam1, Girish Joglekar1, Venkat Venkatasubramanian1, Gintaras Victor Reklaitis2, Kenneth R. Morris3, Anthony Hlinak4 and Prabir K. Basu5, (1)School of Chemical Engineering, Purdue University, 480 Stadium Mall Drive, West Lafayette, IN 47907, (2)Purdue University, School of Chemical Engineering, 1283 Chemical Engineering Building, West Lafayette, IN 47907, (3)Industrial Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, (4)Abbott Laboratories, IL, (5)Purdue University, 1911 Wood Lane, Mount Prospect, IL 60056
Blister Push through Force and Tablet Three Point Bend Strength as Means of Predicting Deblistering Performance
Justin D. Moser1, Craig B. Ikeda1, David Yao2, Jeannie Chow3 and Tzyy-Show Chen1, (1)Pharmaceutical Development, Merck & Co., Inc., West Point, PA 19486, (2)Packaging Technology, Merck & Co., Inc., West Point, PA 19486, (3)Pharmaceutical Development, Merck & Co. ,Inc., West Point, PA 19486
Intermission
Adjuvant-Adsorbed Vaccine Susceptibility to Hydrodynamic Shear
David J. Geer, Kenneth J. Ford, Li Shi, Suhas D. Shelukar, William A. Hunke and Scott D. Reynolds, Merck Research Laboratories, Merck and Co., Inc., West Point, PA 19486
Quantitative Determination of the Role of Geometric and Operating Variables on the Hydrodynamics of the Usp Dissolution Apparatus II
Piero M. Armenante1, Ge Bai1, Russell V. Plank2, Kenneth Ford3, Michael Gentzler3 and Paul Harmon3, (1)New Jersey Institute of Technology, Department of Chemical Engineering, 323 King Blvd., Newark, NJ 07102-1982, (2)Pharmaceutical R&D, Merck & Co., WP 78-110, West Point, PA 19486, (3)Merck & Co., WP 78-110, West Point, PA 19486
Novel Mucoadhesive Formulations Employing pH Responsive Biomaterials
J. Brock Thomas, Department of Chemical Engineering, University of Texas at Austin, 1 University Station, MC C0400, Austin, TX 78712, Nicholas A. Peppas, Department of Chemical Engineering, CPE 3.466, 1 University Station, Code C0400, Austin, TX 78712 and James W. McGinity, Division of Pharmaceutics, University of Texas at Austin, 1 University Station, Stop A1902, Austin, TX 78712

Food, Pharmaceutical & Bioengineering Division